

ARTICLE OPEN



Endothelial cell-derived RSPO3 activates Gai1/3-Erk signaling and protects neurons from ischemia/reperfusion injury

Ting-tao Liu^{1,2,9}, Xin Shi^{3,9}, Hong-wei Hu^{4,9}, Ju-ping Chen^{5,9}, Qin Jiang⁶, Yun-Fang Zhen⁷, Cong Cao³, Xue-wu Liu⁸ and Jian-gang Liu⁴

© The Author(s) 2023

The current study explores the potential function and the underlying mechanisms of endothelial cell-derived R-spondin 3 (RSPO3) neuroprotection against ischemia/reperfusion-induced neuronal cell injury. In both neuronal cells (Neuro-2a) and primary murine cortical neurons, pretreatment with RSPO3 ameliorated oxygen and glucose deprivation (OGD)/re-oxygenation (OGD/R)-induced neuronal cell death and oxidative injury. In neurons RSPO3 activated the Akt, Erk and β -Catenin signaling cascade, but only Erk inhibitors reversed RSPO3-induced neuroprotection against OGD/R. In mouse embryonic fibroblasts (MEFs) and neuronal cells, RSPO3-induced LGR4-Gab1-Gai1/3 association was required for Erk activation, and either silencing or knockout of Gai1 and Gai3 abolished RSPO3-induced neuroprotection. In mice, middle cerebral artery occlusion (MCAO) increased RSPO3 expression and Erk activation in ischemic penumbra brain tissues. Endothelial knockdown or knockout of RSPO3 inhibited Erk activation in the ischemic penumbra brain tissues and increased MCAO-induced cerebral ischemic injury in mice. Conversely, endothelial overexpression of RSPO3 ameliorated MCAO-induced cerebral ischemic injury. We conclude that RSPO3 activates Gai1/3-Erk signaling to protect neuronal cells from ischemia/reperfusion injury.

Cell Death and Disease (2023)14:654; <https://doi.org/10.1038/s41419-023-06176-2>

INTRODUCTION

Cerebral infarction accounts for over 75% of acute cerebrovascular disease [1, 2]. Damage or occlusion of blood vessels results in ischemic and hypoxic injury in the ischemic area and adjacent brain tissues [3, 4]. Cerebral ischemia-reperfusion injury will aggregate brain injury [1, 5], causing mitochondrial dysfunction, oxidative injury, Ca^{2+} overload, blood brain barrier damage, inflammation and nitric oxide toxicity, eventually leading to apoptotic death of neurons [6, 7]. Oxygen and glucose deprivation (OGD)/re-oxygenation (OGD/R) [8] model mimics ischemia/reperfusion injury to cultured neurons (and neuronal cells) [9–12].

The R-spondin (RSPO) family of proteins include four primary members, including R-spondin1 (RSPO1), R-spondin2 (RSPO2), R-spondin3 (RSPO3), and R-spondin4 (RSPO4) [13]. RSPOs have similar protein structures consisting of two amino-terminal furin-like (FU1-FU2) repeats, a thrombospondin (TSP) domain and a basic amino acid-rich carboxy-terminal domain (BR) [13], but perform markedly different functions [13–15]. The FU1, FU2 and TSP/BR domains connect RSPO proteins with the ubiquitin ligase ZNRF3 (Zinc And Ring Finger 3)/RNF43 (Ring Finger Protein 43), leucine-rich repeat G protein-coupled receptor 4–6 (LGR4–6) and heparin sulfate proteoglycan (HSPG) [16–23].

RSPO3 has been shown to play an essential role in vascular development and angiogenesis [24, 25]. Conditional RSPO3 knockout (KO) in the developing heart resulted in defective development of the secondary cardiac field, showing pericardial edema and marked vascular congestion [26]. Scholz et al. found that depletion of endothelial-derived RSPO3 was the primary cause of the death of RSPO3 KO mice [24]. RSPO3 in endothelial cells was shown to regulate vascular remodeling, inhibit endothelial cell apoptosis [24], and promote coronary formation in angiogenic regions of the heart [27].

Recent studies report that RSPO3 activates Wnt signaling to promote stem cell recovery and epithelial repair [28]. Contrarily, stromal depletion of RSPO3 impedes regeneration of crypt [28]. Sigal et al. demonstrated that RSPO3 induces the differentiation of basal Lgr5⁺ cells into secretory cells, inhibiting *H. pylori* colonization in gastric glands through the secretion of intelectin-1 and other antimicrobial factors [29]. Zhou et al. showed that endothelial KO of RSPO3 suppressed anti-inflammatory interstitial macrophage formation and caused severe inflammatory response in endotoxemic mice [30]. Here we examined the potential function and the underlying mechanisms of endothelial cell-derived RSPO3 against ischemia/reperfusion-induced neuronal cell injury.

¹Shandong University, Department of Neurology, Shandong Provincial Hospital, Jinan, China. ²Department of Neurology, Shouguang Hospital of T.C.M, Shouguang, China. ³Department of Neurology and Clinical Research Center of Neurological Disease, The Second Affiliated Hospital of Soochow University, Suzhou, China. ⁴Department of Neurosurgery, The First Affiliated Hospital of Soochow University, Suzhou, China. ⁵Department of Neurology, Changshu Hospital of Traditional Chinese Medicine, Changshu, China. ⁶The Fourth School of Clinical Medicine, Nanjing Medical University, Nanjing, China. ⁷Department of Orthopedics, Children's hospital of Soochow University, Suzhou, China. ⁸Department of Neurology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China. ⁹These authors contributed equally: Ting-tao Liu, Xin Shi, Hong-wei Hu, Ju-ping Chen. ✉email: zhenyfsz9@163.com; caocong@suda.edu.cn; snlxw1966@163.com; liujiangang@suda.edu.cn
Edited by Professor Boris Zhivotovsky

Received: 22 March 2023 Revised: 19 September 2023 Accepted: 26 September 2023

Published online: 07 October 2023

MATERIALS AND METHODS

Reagents

As described in our previous study [31], the recombinant human RSPO3 was purchased from Sigma-Aldrich (SRP3323), and both human (human umbilical vein endothelial cells/HUVECs) and murine cells (mouse embryo fibroblasts/MEFs) were response to it [31]. Puromycin, polybrene, PD98059 and U0126 were purchased from Sigma-Aldrich. Fetal bovine serum (FBS), medium, antibiotics and other cell culturing reagents were purchased from Gibco Co. (Shanghai, China). Antibodies utilized in this study were described in our previous studies [31–34] or otherwise mentioned. The primers, sequences and viral constructs were obtained from Genechem Co. (Shanghai, China), unless otherwise mentioned. The recombinant RSPO3 protein was first dissolved in PBS at 50 µg/mL as the stock solution, which was then added directly to medium of the neuronal cells/neurons.

Cells

The wild-type (WT) mouse embryonic fibroblasts (MEFs), the Gai1 and Gai3 double knockout (DKO) MEFs, Gai1, Gai2, or Gai3 single knockout (SKO) MEFs, WT and Gab1 knockout (KO) MEFs were described in our previous studies [31–34]. Neuro-2a cells were purchased from the Cell Bank of CAS Shanghai Institution of Biological Science (Shanghai, China). Expression of Gai1, Gai2, and Gai3 were always checked [33–37]. For isolation and primary culture of murine cortical neurons, fronto-lateral cortical lobes from embryonic day 15.5 (E15.5) C57BL/6 mice fetuses were dissected. Afterwards, brain cells were chemically dissociated by adding trypsin and DNase I (Sigma-Aldrich) and were resuspended in serum-free B27 Neurobasal medium (Gibco) plus penicillin, streptomycin and L-glutamine (Gibco). Cells were placed on poly-L-lysine (Sigma Aldrich)-coated culture plates or glass coverslips and maintained at 37 °C in a saturated atmosphere with 95% air and 5% CO₂. At day-10 (DIV), 91.52 ± 3.57% of cells were primary murine cortical neurons. The purity was calculated by measuring NeuN-positive nuclei percentage. Newborn mice (C57BL/6 J) were sacrificed at postnatal day 1 (P1). The brain cortices were dissected and cut into small pieces, and primary cells dissociated with trypsin. The cells were then strained through 70 µm cell strainer and plated in culture flasks coated with poly-D-lysine. Mixed glial cells were cultured for 7–9 days. The culture flask was then placed vertically for 5 min, then the culture bottle is gently patted for 10–15 min by hand, and the separation of microglia is observed under the microscope every 5 min. At this time, the microglia growing in the upper layer fell off into the culture medium. Microglia were collected, centrifuged at 1200 rpm for 5 min, resuspended and seeded onto poly-L-lysine pre-coated culture dish/flasks. Microglia were verified by positive staining of Iba-1 (over 95%-positive, Abcam). After collecting microglia, the culture flask was shaken at 250 rpm for 18 h to remove non-astrocytes. Astrocyte phenotype was evaluated by cell exhibiting a characteristic morphology and positive staining for the astrocytic marker glial fibrillary acid protein (GFAP, over 95%-positive, Abcam). The protocols of the present study were approved by the Ethics Committee and Institutional Animal Care and Use Committee (IACUC) of Soochow University (2019BR0151).

Isolation and primary culturing of mouse brain endothelial cells

The detailed protocols were described previously [38]. Briefly, C57BL/6J mice were sacrificed. The brain cortices were dissected and cut into small pieces. Tissues were then subject to two rounds of enzymatic dissociation and myelin separation as described [38]. FBS was then added to block the trypsin/collagenase activity. The solution was then filtered through a 10 nm sterile mesh adapted to a 50 mL conical tube. The mesh was further washed with medium to recover more cells and was centrifuged at 800 × g for 15 min at room temperature with the supernatant discarded. The pellet was then cultured in described 20% FBS-containing DMEM/F-12 medium plus human basic fibroblast growth factor (bFGF) and bovine sodium heparin [38]. Medium was renewed every 48 h. The passage of primary endothelial cells was carried out after seven days of culture and endothelial cells enrichment was obtained through passaging as described [38]. The purity of the endothelial cells, 94.03 ± 4.16%, was calculated by measuring the percentage of cells with positive vascular cell adhesion molecule 1 (VCAM-1) fluorescence staining.

OGD/re-oxygenation (OGD/R)

OGD/R procedure was described previously [9, 39]. Neuronal cells, primary murine neurons or mouse brain endothelial cells, with the applied genetic modifications or treatments, were cultivated in glucose-free medium and

were placed in a sealed airtight chamber with continuous flux of gas (95% N₂/5% CO₂) for 4 h (OGD). Cells were then re-oxygenated (OGD/R) for designated time periods. Neuronal cells in the norm-oxygenated medium containing glucose were labeled as “Mock” control cells.

Lipid peroxidation assays

Neuronal cells were seeded into the poly-L-lysine-coated six-well plates at 120,000 cells per well. Following the designated treatment, the thiobarbituric acid reactive substances (TBAR)-reactive malondialdehyde (MDA) concentration was measured. The latter reacts with the thiobarbituric acid and forms the pink complex. The reaction buffer [40, 41] was mixed with cell lysates and the mix was boiled at 100 °C for 30 min. Thereafter, the mix was centrifuged at 3500 rpm for 12 min and the absorbance of pink color was measured at 535 nm.

Genetic modifications in vitro

Gai1 and Gai3 double silencing by targeted lentiviral shRNA, ectopic Gai1 and Gai3 overexpression by adenoviral constructs, CRISPR/Cas9-induced Gai1 and Gai3 double knockout (DKO), rescuing Gai1 or Gai3 in Gai1/3 DKO MEFs, the dominant negative (DN)-Gai1 or DN-Gai3, or the empty vector (“Vec”), were reported in our previous studies [31–37, 42]. The GV369 constructs containing the LGR4 shRNA (sh-LGR4-s1 or sh-LGR4-s2), Gab1 shRNA or Gab1 cDNA were provided by Genechem (Shanghai, China), each was transduced to HEK-293 cells by Lipofectamine 3000 to generate lentivirus. Virus were thereafter enriched, purified and quantified, and were added (at MOI = 15) to cultured cells/neurons. Stable cells were formed after selection using puromycin-containing medium.

Fluorescence dye assays in vitro

The detailed protocols have been described in our previous studies [43, 44]. Neuronal cells or neurons were placed onto poly-L-lysine pre-coated coverslips at 60–70% confluence and were subject to the designated treatments. Cells were then fixed by using 4% formaldehyde solution for 12 min and were permeabilized by Triton X-100 solution (0.2%) for additional 7.5 min at room temperature. Cells were then stained with the applied fluorescence dyes (JC-1, CellROX, TUNEL and DAPI). Fluorescence images were taken through the fluorescence microscopy (Zeiss) and the fluorescence intensity was measured from five random views of each treatment.

Other assays

The detailed protocols of Western blotting, co-immunoprecipitation (Co-IP), quantitative reverse transcription PCR (qRT-PCR), cell counting kit-8 (CCK-8), medium lactate dehydrogenase (LDH) releasing, Caspase-3/–9 activity assay, as well as single strand DNA (ssDNA) ELISA and Histone DNA ELISA are widely utilized in our previous studies [43, 45–49]. Figure S4 listed the uncropped blotting images.

The middle cerebral artery occlusion (MCAO) model and 2,3,5-triphenyltetrazolium hydrochloride (TTC) staining

Mice (all male, 9–10 week old, 21–22 g), from Changzhou Cavens Experimental Animal Co (Changzhou, China), were anesthetized with isoflurane (3% for induction and 1.5% during the rest of the surgical procedure under 30% oxygen and 70% nitrogen). A silicon-coated 6–0 nylon suture was introduced into the external carotid artery and advanced up to the internal carotid artery to occlude the middle cerebral artery for 1 h followed by reperfusion. The rectal temperature of the mice was always maintained at 37.0 °C using a temperature-control heating pad. Animal regional cerebral blood flow (rCBF) was monitored via a transcranial laser Doppler, and mice with the rCBF higher than 20% of original baseline value were excluded. The nylon suture was removed 1 h after common carotid artery occlusion, and the skin incision was theater closed. The “Mock” group mice underwent the same surgical procedures but without MCAO. Twenty-four hours after reperfusion, the brain was collected, sectioned and stained with TTC (1%, at 37 °C for 1 h). Afterwards, the brain sections were fixed and photographed. The infarction area ratio = (contralateral hemispheric volume - ipsilateral non-infarct volume)/contralateral hemispheric volume × 100%. The brain area of each section was measured using the National Institutes of Health Image program (Image J 1.37 v). The animal protocols were conducted in according to the Institutional Animal Care and Use Committee and the Ethic Committee of Soochow University (2019BR0151).




Fig. 1 RSPO3 ameliorates OGD/R-induced neuronal cell death. Neuro-2a neuronal cells (A, B), the primary murine cortical neurons (C, D) were pretreated with RSPO3 (at 50 ng/mL, expert for A, B) or the vehicle control (“Veh”) for 30 min, followed by oxygen glucose deprivation (OGD) for 4 h and then re-oxygenation (OGD/R) for 48 h, viability and cell death were tested by CCK-8 (A, C) and medium LDH releasing (B, D) assays, respectively. “Mock” stands for the mock treatment (norm-oxygenated medium with glucose). Data were presented as mean \pm standard deviation (SD, $n = 5$). * $P < 0.001$ vs. “Mock” cells with Veh treatment. # $P < 0.001$ vs. OGD/R with “Veh” pretreatment. Each experiment was repeated five times and similar results were obtained.

Immunohistofluorescence

Mice were anaesthetized and underwent intracardial perfusion with 0.9% saline followed by 4% paraformaldehyde. Brains were post-fixed in paraformaldehyde (4%) for 24 h at 4°C and then maintained under 30% sucrose. Brains were sectioned with a sliding-freezing microtome (Leica). Mouse brain sections were incubated with blocking buffer (0.4% Triton X-100 and 5% goat serum) for 1 h. Brain sections were incubated with primary antibody overnight at 4°C, washed 3 times in PBS, then incubated with secondary antibodies for 2 h at room temperature. The following primary antibodies were utilized: rabbit anti-Erk1/2 (phospho Thr202/Tyr204) (Cell Signaling Technology, 4370 s, 1:100), mouse anti-NeuN (Cell Signaling Technology, 94403 S, 1:100), rabbit anti-RSPO3 (Proteintech, 17193-1-AP, 1:100). All secondary antibodies were used at a concentration of 1:500. Secondary antibodies were goat anti-rabbit Alexa 488 (Abcam, ab150077) and goat anti-mouse Alexa 594 (Abcam, ab150116).

Neurological (Garcia) scores

As reported [50], 24 h after reperfusion, the neurological functions of MCAO mice and Mock mice were measured. Six grades were involved in Garcia scores containing spontaneous activity, spontaneous movements of all limbs, movements of forelimbs, climbing wall of wire cage, touch of trunk and Vibrissae touch. The minimum score 0 for each grade is severest deficit, and the maximum score is 3 (normal) [50]. The total score is 18 (healthy), and the lower score indicated serious deficits [50].

The foot-fault test

For testing of motor coordination in MCAO mice and Mock mice, foot-fault tests were performed 14 days after MCAO using the described protocol [51]. In brief, mice were placed on a horizontal grid floor and were allowed to walk for 2 min. A foot fault was recorded when the mouse's foot miss-stepped on the grid and the foot fell downwards through the opening between the grids. All four limbs were observed for misses. The percentage of total foot faults was recorded [51].

Genetic modifications in vivo

RSPO3 shRNA or RSPO3 cDNA sequence [NM_028351.3] was inserted into an adeno-associated virus 5 (AAV5)-TIE1 construct (reported in our previous studies [31, 32, 42, 52]) that contained sequence of the endothelial specific promoter TIE1 [52]. The constructs were individually transfected to HEK-293 cells to generate adenovirus, which was intravitally injected to the mice as reported (at 2 μ L virus per mouse, 0.2 μ L per minute) [52]. The TIE1-DIO-Cre C57 mice were commercial available and were reported previously [52]. The AAV5 construct encoding FLEX plus the dCas9-murine RSPO3 sgRNA sequence, or AAV5-FLEX-CRISPR/Cas9-RSPO3-KO, was designed by Genechem (Shanghai, China), and AAV generated and was intravitally injected to TIE1-DIO-Cre C57 mice (at 2 μ L virus per mouse, 0.2 μ L per minute). For infection of primary neurons or endothelial cells, the RSPO3 shRNA or RSPO3 cDNA were inserted into the GV369 construct containing the TIE1 promoter sequence, which was then transduced to HEK-293 cells to generate lentivirus. Lentivirus was added to the cells for 96 h.

Statistical analysis

Data in this study were all with normal distribution and were presented as mean \pm standard deviation (SD). The two-tailed unpaired *t*-test was utilized to compare statistical difference between two specific groups. One-way analysis of variance (ANOVA) plus Tukey's post hoc tests were utilized for multiple groups (unless otherwise mentioned in Fig. 1). $P < 0.05$ was statistically significant.

RESULTS

RSPO3 ameliorates OGD/R-induced neuronal cell death

To test the potential effect of RSPO3 on ischemia/reperfusion-caused neuronal damage, in vitro experiments were carried out on Neuro-2a neuronal cells [53, 54]. Neuro-2a cells were maintained under oxygen glucose deprivation (OGD) for 4 h and then cultured




Fig. 2 RSPO3 ameliorates OGD/R-induced neuronal cell apoptosis. Neuro-2a neuronal cells (A–F) or the primary murine cortical neurons (G–J) were pretreated with RSPO3 (at 50 ng/mL) or the vehicle control (“Veh”) for 30 min, followed by oxygen glucose deprivation (OGD) for 4 h and then re-oxygenation (OGD/R) for applied time periods, the caspase-3/9 activities (A, B, G) were tested; Expression of listed proteins in total cell lysates were shown (C, H); Histone-bound DNA contents were measured (D). Cell apoptosis was examined by TUNEL staining (E, F, I, J). Data were presented as mean \pm standard deviation (SD, $n = 5$). * $P < 0.001$ vs. “Mock” cells. # $P < 0.001$ vs. OGD/R with “Veh” pretreatment. Each experiment was repeated five times and similar results were obtained. Scale bar = 100 μ m.

in the complete medium (“re-oxygenation”, OGD/R) for another 48 h. OGD/R decreased CCK-8 viability (Fig. 1A) and provoked Neuro-2a cell death as evidenced by increased LDH release (Fig. 1B).

Testing whether exogenously-added RSPO3 was neuroprotective, pretreatment with RSPO3 was found to inhibit OGD/R-induced cytotoxicity in Neuro-2a cells (Fig. 1A, B). The RSPO3-induced neuronal protection was dose-dependent and was significant at 50 and 100 ng/mL (Fig. 1A, B). Treatment with RSPO3 alone at the tested concentrations failed to significantly alter CCK-8 viability (Fig. 1A) and LDH release (Fig. 1B). Although higher concentrations of RSPO3 inhibited the reduction in OGD/R-induced Neuro-2a cell viability (Fig. S1A) and LDH medium release (Fig. S1B), the 50–100 ng/mL concentration exhibited better neuroprotection (Fig. S1A, B). Titration results revealed that RSPO3, at 50 ng/mL, robustly inhibited OGD/R-induced neuronal cell death, and this concentration was selected for the following

studies. We also found that pretreatment of RSPO3 for 15’-60’ significantly inhibited OGD/R-induced cytotoxicity in Neuro-2a cells (Fig. S1C, D), with 30’ of pretreatment showing the most significant neuroprotective effects (Fig. S1A, B).

Testing RSPO3 in primary neurons, OGD/R decreased cell viability in primary murine cortical neurons (Fig. 1C) and increased LDH release (Fig. 1D), which were ameliorated by RSPO3 (50 ng/mL) pretreatment (Fig. 1C, D).

RSPO3 ameliorates OGD/R-induced neuronal cell apoptosis

Apoptosis is the primary mechanism of OGD/R-induced neuronal cytotoxicity [55–58]. Following OGD/R stimulation, the relative caspase-3 activity (Fig. 2A) and the relative caspase-9 activity (Fig. 2B) were significantly increased in Neuro-2a cells. As shown in Fig. 2C, OGD/R treatment led to cleavage of caspase-3, caspase-9 and poly (ADP-ribose) polymerase (PARP), and histone-bound DNA counts were increased in OGD/R-stimulated Neuro-2a cells (Fig. 2D).




Fig. 3 RSPO3 ameliorates OGD/R-induced oxidative injury in neuronal cells. Neuro-2a neuronal cells (A–E) or the primary murine cortical neurons (F–H) were pretreated with RSPO3 (at 50 ng/mL) or the vehicle control (“Veh”) for 30 min, followed by oxygen glucose deprivation (OGD) for 4 h and then re-oxygenation (OGD/R) for 24 h, mitochondrial depolarization (A, F), ROS production (B, C, G), lipid peroxidation (D) and ssDNA contents (E, H) were tested by the described assays. “Mock” stands for the mock treatment (norm-oxygenated medium with glucose). Data were presented as mean \pm standard deviation (SD, $n = 5$). * $P < 0.001$ vs. “Mock +Veh” group. # $P < 0.001$ vs. OGD/R with “Veh” pretreatment. Each experiment was repeated five times and similar results were obtained. Scale bar = 100 μ m.

Remarkably, RSPO3 (at 50 ng/mL) pretreatment largely attenuated OGD/R-induced apoptosis in Neuro-2a cells (Fig. 2A–D), and decreased the percentage of TUNEL-positively stained nuclei (Fig. 2E, F). In primary murine cortical neurons, RSPO3 (at 50 ng/mL) pretreatment ameliorated OGD/R-induced caspase-3 activation (Fig. 2G), caspase-3/caspase-9/PARP cleavage (Fig. 2H) and decreased TUNEL-positively stained nuclei ratio (Fig. 2I, J).

RSPO3 ameliorates OGD/R-induced oxidative injury in neuronal cells

OGD/R disrupts mitochondrial function, causing ROS production and oxidative injury, serving as a primary cause of neuronal cell death/apoptosis [8–10, 59–61]. In Neuro-2a cells, OGD/R caused mitochondrial depolarization (Fig. 3A), indicated by the conversion of JC-1 red fluorescence to green fluorescence (monomers,




Fig. 4 RSP03-induced neuroprotection against OGD/R is abolished after Erk1/2 inhibition. Neuro-2a neuronal cells (A) or the primary murine cortical neurons (B) were treated with RSP03 (at 50 ng/mL) or the vehicle control (“Veh”) for indicated time periods, and expression of listed proteins was shown. Neuro-2a neuronal cells were pretreated with PD98059 or U0126 (10 μ M, for 30 min), followed by RSP03 (50 ng/mL) treatment for 30 min, cells were then maintained under oxygen glucose deprivation (OGD) for 4 h and then re-oxygenation (“OGD/R”) for 48 h, cell viability and death were tested by CCK-8 (C) and medium LDH release (D) assays, respectively. “Mock” stands for the mock treatment (norm-oxygenated medium with glucose). Data were presented as mean \pm standard deviation (SD, $n = 5$). * $P < 0.001$ vs. “Veh” treatment (A, B). # $P < 0.001$ (C, D). Each experiment was repeated five times and similar results were obtained.

Fig. 3A). ROS production was increased as shown by an increase in CellROX red fluorescence intensity (Fig. 3B, C) in OGD/R-stimulated Neuro-2a neuronal cells. Pretreatment with RSP03 (50 ng/mL) inhibited OGD/R-induced mitochondrial depolarization (Fig. 3A) and ROS production (Fig. 3B, C) in Neuro-2a cells. OGD/R caused lipid peroxidation (TBAR intensity increasing, Fig. 3D) and DNA breaks (ssDNA accumulation, Fig. 3E). Both were significantly ameliorated after RSP03 pretreatment (Fig. 3D, E).

In the primary murine cortical neurons, OGD/R similarly provoked mitochondrial depolarization (JC-1 green monomer accumulation, Fig. 3F), ROS production (CellROX, Fig. 3G) and DNA breaks (ssDNA accumulation, Fig. 3H). These actions were ameliorated following RSP03 pretreatment (Fig. 3F–H), demonstrating that RSP03 can efficiently ameliorate OGD/R-induced oxidative injury in neuronal cells.

RSP03-induced neuroprotection against OGD/R is abolished after Erk1/2 inhibition

To study the signaling mechanism of RSP03-induced neuroprotection, Neuro-2a cells were treated with RSP03 (50 ng/mL) and levels of phosphorylated-Akt, phosphorylated-Erk1/2 and active (non-phosphorylated) β -Catenin were increased (Fig. 4A). Similarly, in primary murine cortical neurons RSP03 treatment augmented Akt, Erk1/2 and active β -Catenin (Fig. 4B). Importantly, co-treatment with Erk inhibitors, including PD98059 and U0126,

abolished RSP03-induced neuroprotection against OGD/R in Neuro-2a cells (Fig. 4C, D). Conversely, the β -Catenin inhibitor FH535 and the Akt inhibitor LY294002 had no effect on RSP03-induced neuroprotection against OGD/R in Neuro-2a cells (Fig. S2A, B). Notably, FH535 downregulated β -Catenin target gene *LEF1* expression in RSP03-treated cells (Fig. S2C) and LY294002 blocked RSP03-induced Akt phosphorylation (Fig. S2D). These results show that Erk activation is essential for RSP03-induced neuroprotection against OGD/R.

Gai1 and Gai3 are required for RSP03-induced Erk activation and neuroprotection against OGD/R

Our previous studies have established the critical roles of Gai1 and Gai3 (but not Gai2) proteins in transducing Erk1/2 activation of multiple receptors [32, 34, 35, 42]. We therefore tested whether Gai proteins are also important for RSP03-induced Erk activation and neuroprotection. As shown, RSP03-induced Erk1/2 phosphorylation was blocked in Gai1 and Gai3 double knockout (DKO) mouse embryonic fibroblasts (MEFs) (Fig. 5A). Gai1 or Gai3 single knockout (SKO) resulted in partial inhibition of Erk1/2 phosphorylation in RSP03-treated MEFs (Fig. 5A). Gai2 SKO in MEFs failed to significantly reduce RSP03-induced Erk1/2 phosphorylation (Fig. 5B).

Neuro-2a cells were infected with Gai1 shRNA lentivirus and Gai3 shRNA lentivirus and stable cells selected (“Gai1/3-DshRNA”).




Fig. 5 *Gai1* and *Gai3* are required for RSPO3-induced Erk activation and neuroprotection against OGD/R. Wild-type (WT), *Gai1/3* double knockout (DKO), *Gai1*, *Gai2* or *Gai3* single knockout (SKO) mouse embryonic fibroblasts (MEFs) were treated with RSPO3 (at 50 ng/mL) and cultivated for indicated time periods, expression of listed proteins was shown (A, B). Neuro-2a cells, with the *Gai1* shRNA plus the *Gai3* shRNA (“*Gai1/3*-DshRNA”), the scramble control shRNA (“scr-shRNA”), were established and expression of listed genes and proteins was shown (C, D); Cells were treated with RSPO3 (50 ng/mL) or vehicle control and cultured for 15 min, expression of listed proteins was tested (E). *Gai1/3*-DshRNA or scr-shRNA Neuro-2a cells were pretreated with RSPO3 (50 ng/mL) for 30 min, cells were then maintained under oxygen glucose deprivation (OGD) for 4 h and then re-oxygenation (“OGD/R”) for the applied time periods, cell viability, death and apoptosis were tested by CCK-8 (F), medium LDH release (G) and nuclear TUNEL staining (H) assays, respectively. “Mock” stands for the mock treatment (normo-oxygenated medium with glucose). Data were presented as mean \pm standard deviation (SD, $n = 5$). * $P < 0.001$ vs. “WT” MEFs/“scr-shRNA”. # $P < 0.001$. Each experiment was repeated five times and similar results were obtained.

Control cells were stably transfected with scramble control shRNA lentivirus (“scr-shRNA”) (Fig. 5C, D). *Gai1* and *Gai3* mRNA and protein expression levels were robustly downregulated in *Gai1/3*-DshRNA (Fig. 5C, D), leaving *Gai2* mRNA and protein unchanged (Fig. 5C, D). Knockdown of *Gai1* and *Gai3* in Neuro-2a cells inhibited RSPO3-provoked Erk1/2 phosphorylation (Fig. 5E). These results support that *Gai1* and *Gai3* are required for RSPO3-induced Erk activation in neuronal cells. Remarkably, *Gai1/3* silencing reversed RSPO3-induced inhibition of OGD/R-caused viability reduction (Fig. 5F), cell death (Fig. 5G) and apoptosis (Fig. 5H).

RSPO3 induces LGR4-Gab1-Gai1/3 association, required for downstream Erk activation in neuronal cells

As our recent study reported that RSPO3 induced *Gai1/3* association with LGR4 and Gab1 in endothelial cells, mediating downstream Akt-mTOR activation to promote angiogenesis [31], we explored whether RSPO3-induced LGR4-Gab1-Gai1/3 association is important for Erk activation. Co-immunoprecipitation (Co-IP) assay results in Neuro-2a cells revealed that RSPO3 (50 ng/mL) promotes LGR4-Gab1-Gai1/3 association (Fig. 6A). Silencing LGR4, using stable Neuro-2a cells expressing LGR4 shRNAs [31], robustly decreased LGR4 protein expression and inhibited RSPO3 (50 ng/mL)-provoked Gab1 and Erk1/2 phosphorylation in Neuro-2a cells, without affecting *Gai1/2/3*, Gab1 and Erk1/2 protein expression (Fig. 6B). In Neuro-2a cells, RSPO3-mediated inhibition of OGD/R-induced cell death and apoptosis was abolished by shRNA-induced silencing of LGR4 (Fig. 6C).

To further support that LGR4-Gab1-Gai1/3 association is required for RSPO3-induced Erk1/2 activation, dominant negative

(“DN”) mutants of *Gai1* and *Gai3* (“DN-*Gai1/3*”) were transduced into Neuro-2a cells. These *Gai1/3* mutants replace the conserved Gly (G) residue with Thr (T) in the G3 box preventing *Gai1/3* association with adaptor/associated proteins [37, 62]. As shown, DN-*Gai1/3* inhibited Gab1 and Erk1/2 activation in response to RSPO3 in Neuro-2a cells (Fig. 6D). RSPO3-induced Erk1/2 phosphorylation was abolished in Gab1 KO MEFs (Fig. 6E).

Endothelial knockdown of RSPO3 enhances MCAO-caused cerebral ischemic injury

We next examined whether the expression of RSPO3 is changed in mouse brain tissue after cerebral ischemia/reperfusion. Ischemic penumbra brain tissues were collected 3 h, 6 h, 9 h and 12 h following MCAO. As shown, RSPO3 protein levels gradually increased in the ischemic penumbra brain tissues of MCAO mice (Fig. 7A). Moreover, RSPO3 mRNA in brain tissues was significantly upregulated 6–12 h after MCAO (Fig. 7B). Notably, RSPO3 protein was high in primary murine brain endothelial cells (VACM-1-positive, “Endothelial cells”) (Fig. S3A, B). In contrast, RSPO3 expression was extremely low in NeuN-positive primary murine cortical neurons and GFAP-positive primary murine astrocytes (Fig. S3A), and null in primary murine microglia (Iba-1-positive staining, Fig. S3A). In a time-dependent manner, OGD/R stimulation increased mRNA (Fig. S3C) and protein (Fig. S3D) expression of RSPO3 in primary murine brain endothelial cells. Next, the medium samples, free of debris and cells, were collected and were centrifuged. The supernatant containing secreted proteins was thereafter collected and was tested by Western blotting assays. Results show that production of RSPO3 in the medium was




Fig. 6 RSPO3 induces LGR4-Gab1-Gai1/3 association, required for downstream Erk activation in neuronal cells. Neuro-2a cells were treated with RSPO3 (50 ng/mL) and cultivated for 5–15 min, LGR4 association with Gab1 and Gai1/3 was examined by co-immunoprecipitation (“Co-IP”) assays (**A**); Neuro-2a cells, stably expressing the lentiviral LGR4 shRNA (sh-LGR4-s1 and sh-LGR4-s2, representing two different sequences) or the scramble control shRNA (“scr-shRNA”), were treated with RSPO3 (50 ng/mL) and cultured for 15 min, expression of listed proteins was tested (**B**); Alternatively, cells were pretreated with RSPO3 (50 ng/mL) for 30 min, cells were then maintained under oxygen glucose deprivation (OGD) for 4 h and then re-oxygenation (“OGD/R”) for the applied time periods, cell death and apoptosis were tested by medium LDH release and nuclear TUNEL staining assays, respectively (**C**). Neuro-2a cells, stably expressing the dominant negative (DN)-Gai1 plus DN-Gai3 (“DN-Gai1/3”) or the empty vector (“Vec”), were treated with RSPO3 (50 ng/mL) and cultured for 15 min, expression of listed proteins was shown (**D**). Wild-type (WT) and Gab1 knockout (KO) mouse embryonic fibroblasts (MEFs) were treated with RSPO3 (50 ng/mL) and cultivated for 15–45 min, expression of listed proteins was shown (**E**). Data were presented as mean \pm standard deviation (SD, $n = 5$). * $P < 0.001$ vs. “Veh”/“scr-shRNA”/“Vec”/“WT MEFs”. # $P < 0.001$ (**C**). Each experiment was repeated five times and similar results were obtained.

significantly increased in OGD/R-stimulated primary murine endothelial cells (Fig. S3E).

To demonstrate the neuroprotective activity of RSPO3 in vivo, RSPO3 was specifically knocked down in endothelial cells using an shRNA-expressing adenovirus (AAV5 construct, containing TIE1 promoter region) injected into the lateral ventricle: “RSPO3-eKD”. The control mice received lateral ventricle injection of scramble control shRNA adenovirus (“shC”, AAV5-TIE1 construct). After 20 days, the MCAO procedure was applied to both RSPO3-eKD and shC mice. Twelve hours later, MCAO-induced RSPO3 expression and Erk activation were largely inhibited in the RSPO3-eKD mice’s ischemic penumbra brain tissue (Fig. 7C). RSPO3 and IB-4 (the endothelial cell marker [42, 52]) double fluorescence staining results in the mouse brain sections confirmed in vivo endothelial knockout of RSPO3 in RSPO3-eKD mice (Fig. 7C, the right panel). RSPO3 green fluorescence signaling was primarily localized in IB-4-positive endothelial cells in shC control mice (Fig. 7C, the right panel). Mouse brain immunofluorescence staining further confirmed Erk inhibition in neurons (NeuN-positive staining) of MCAO-treated RSPO3-eKD mice (Fig. 7D).


In RSPO3-eKD mice, MCAO cerebral ischemic injury significantly enlarged the infarct area (TTC staining) (Fig. 7E), and RSPO3 endothelial silencing augmented MCAO-induced neuronal

apoptosis. Cleaved-caspase-3/caspase -9/PARP levels were increased in the ischemic penumbra brain tissues of RSPO3-eKD mice (Fig. 7F). TUNEL/NeuN fluorescence staining showed that RSPO3-eKD augmented MCAO-induced apoptosis and increased TUNEL-positive neurons in ischemic penumbra brain tissues of MCAO mice (results quantified in Fig. 7G). After MCAO, the neurological scores were much worse in RSPO3-eKD mice (Fig. 7H). The foot-fault ratio, tested 14 days after MCAO, was also significantly higher in RSPO3-eKD mice (Fig. 7I).

To study the potential neuroprotective effect of endothelial cell-derived RSPO3 in vitro, treatment of primary murine cortical neurons with the conditioned medium of OGD/R-stimulated primary murine brain endothelial cells (“ECs”) inhibited the OGD/R-induced viability reduction (Fig. S3F) and cell death (Fig. S3G). The neuroprotective effect of the conditioned medium of murine brain endothelial cells was largely compromised after silencing RSPO3 (through lv-RSPO3-eKD lentivirus) (Fig. S3F, G).

Endothelial conditional knockout of RSPO3 exacerbates MCAO-induced cerebral ischemic injury

To further support the role of endothelial cell-derived RSPO3 against cerebral ischemic injury, the AAV5-FLEX-CRISPR/Cas9-RSPO3-KO was injected into the lateral ventricle of the TIE1-DIO-Cre C57 mice [52], thereby generating RSPO3 endothelial



conditional knockout (RSPO3-eCKO) mice. After 20 days, the MCAO procedure was applied to RSPO3-eCKO mice and TIE1-DIO-Cre control mice. The ischemic penumbra brain tissue was collected 12 h after MCAO, and tissue lysates tested. As shown,

RSPO3 protein expression and Erk1/2 phosphorylation were substantially decreased in brain tissues of RSPO3-eCKO mice (Fig. 8A). RSPO3-eCKO dramatically intensified MCAO-induced cerebral ischemic injury and the infarct area (TTC staining) was

Fig. 7 Endothelial knockdown of RSPO3 intensifies MCAO-caused cerebral ischemic injury. C57BL/6J mice were subject to MCAO procedure for applied time periods, and the ischemic penumbra brain regions were isolated. Expression of listed genes and proteins in the brain tissues were tested (A, B). RSPO3 shRNA-expressing adenovirus (RSPO3 shRNA-TIE1-AAV5, "RSPO3-eKD") or the scramble control shRNA-expressing adenovirus (TIE1-AAV5, "shC") were injected to the lateral ventricle of the mice; After 20 days, the mice were subject to MCAO procedure, and the ischemic penumbra brain regions were isolated and expression of listed proteins was tested (C, F). The ischemic penumbra brain slides were subject to designated fluorescence staining and representative images were shown (C, the right panel, D). TTC staining was employed to stain the ischemic region and results were quantified (E). The brain slides were also subjected to TUNEL/NeuN staining and TUNEL-positive nuclei ratio was recorded (G). Other mice were subject to the behavior tests, the neurological scores were recorded (H, at 24 h) and foot-fault tests (I, at Day-14) were performed. Data were presented as mean \pm standard deviation (SD). * $P < 0.001$ vs. "Mock"/"shC" group. # $P < 0.001$. In each group there were five/seven mice ($n = 5/7$). Scale bar = 100 μm .




Fig. 8 Endothelial conditional knockout of RSPO3 exacerbates MCAO-induced cerebral ischemic injury. AAV5-FLEX-CRISPR/Cas9-RSPO3-KO was injected into the lateral ventricle of the TIE1-DIO-Cre C57 mice (4-week old, male). After 20 days, RSPO3 endothelial conditional knockout (RSPO3-eCKO) mice were established. RSPO3-eCKO mice and TIE1-DIO-Cre control mice were subject to MCAO procedure. After indicated time periods, the ischemic penumbra brain regions were isolated and expression of listed proteins was tested (A). TTC staining was employed to stain the ischemic region and results were quantified (B). Other mice were subject to the behavior tests, the neurological scores were recorded (C, at 24 h) and foot-fault tests (D, at Day-14) were carried out. Data were presented as mean \pm standard deviation (SD). * $P < 0.001$ vs. "TIE1-DIO-Cre" group (A). # $P < 0.001$ (B–D). In each group there were five/seven mice ($n = 5/7$).

substantially enlarged (results quantified in Fig. 8B). When compared to control TIE1-DIO-Cre mice, the neurological scores were much worse in RSPO3-eCKO mice with MCAO (Fig. 8C). Moreover, the foot-fault ratio was significantly higher in RSPO3-eCKO MCAO mice (Fig. 8D). Therefore, RSPO3-eCKO exacerbated MCAO-induced cerebral ischemic injury.

Endothelial RSPO3 overexpression ameliorates MCAO-induced cerebral ischemic injury

Based on the above RSPO3-eKD/-eCKO results, we examined whether endothelial overexpression of RSPO3 could potentially inhibit cerebral ischemic injury in mice. To test this, RSPO3-expressing adenovirus (AAV5, with TIE1 promoter region) was injected into the lateral ventricle, with the aim of overexpressing endothelial RSPO3 ("RSPO3-eOE"). Control mice were injected with empty vector AAV5 ("Vec"). Twenty days later, the MCAO procedure was performed, and the ischemic penumbra brain tissues isolated after 12 h. RSPO3 protein expression was robustly elevated in ischemic penumbra brain regions in RSPO3-eOE mice

(Fig. 9A), and Erk activation augmented (Fig. 9A). The p-Erk fluorescence staining in ischemic penumbra brain tissue sections demonstrated that Erk activation was significantly increased in RSPO3-eOE MCAO mice (Fig. 9B).

RSPO3-eOE significantly inhibited MCAO-induced cerebral ischemic injury in mice. MCAO induced infarct area was reduced in the RSPO3-eOE mice (Fig. 9C), and cleavage of apoptosis proteins inhibited (Fig. 9D), supporting that RSPO3-eOE inhibited MCAO-induced apoptosis. The neurological scores were improved in RSPO3-eOEMCAO mice (Fig. 9E), and the foot-fault ratio significantly reduced (Fig. 9F). Thus, RSPO3-eOE increases Erk activation and inhibits MCAO-induced cerebral ischemic injury in mice.

DISCUSSION

The results of the present study demonstrate the neuroprotective function of RSPO3. In Neuro-2a cells and primary murine cortical neurons, RSPO3 pretreatment largely ameliorated OGD/




Fig. 9 Endothelial RSPO3 overexpression ameliorates MCAO-induced cerebral ischemic injury. The RSPO3-overexpressing adenovirus with TIE1 promoter region (*RSPO3* cDNA-TIE1-AAV5) was injected to mouse lateral ventricle (“RSPO3-nOE” group); The control group mice were injected with the TIE1-AAV5 empty vector adenovirus (“Vec”); After 20 days, MCAO was applied to the mice. After indicated time periods, the ischemic penumbra brain regions were isolated and expression of listed proteins in the brain tissues was measured (**A**, **D**). The ischemic penumbra brain slides were subject to designated fluorescence staining and representative images were shown (**B**). The ischemic region was stained by TTC and results were quantified (**C**). Mice were also subject to the behavior tests, the neurological scores were recorded (**E**, at 24 h) and foot-fault tests (**F**, at Day-14) were performed. Data were presented as mean \pm standard deviation (SD). $^{\#}P < 0.001$. In each group there were five/seven mice ($n = 5/7$). Scale bar = 100 μ m.

R-induced oxidative injury, neuronal cell death and apoptosis. In vivo, RSPO3 expression was increased in the ischemic penumbra brain tissues of MCAO mice. Endothelial knockdown or endothelial conditional knockout of RSPO3 intensified MCAO-induced cerebral ischemic injury. Endothelial RSPO3 overexpression ameliorated cerebral ischemic injury, demonstrating that endothelial cell-derived RSPO3 protects neuronal cells from ischemia/reperfusion injury.

Recent studies have reported that activation of the Erk signaling cascade by a number of different agents can exert significant neuroprotection against ischemic injury in vitro and in vivo. Liu et al. reported that heparin activation of the Erk-CREB-PTN-syndecan-3 cascade attenuated ischemia/reperfusion neuronal injury [63]. Zhao et al. demonstrated that cytosine inhibits cerebral ischemia/reperfusion injury in mice by activating the NR2B-ERK-CREB cascade [64]. Quercetin activates both Erk and Akt signaling

to protect against neuronal ischemia/reperfusion injury [65]. Feng et al. reported that a novel diarylacetyl hydrazone derivative A11 ameliorated ischemic injury via activation of Erk [66].

The role of RSPO3 on Erk signaling is inconsistent between different studies, which could be dependent on different cell types. Chen et al. reported that RSPO3 promoted JEG-3 cell growth by activating Erk and Akt signaling cascades [67]. Similarly, Gu et al. found that loss of RSPO3 resulted in decreased Erk phosphorylation in prostate cancer cells [68]. However, RSPO3 silencing was found to enhance Erk signaling in human adipose-derived stem cells [69]. We show that RSPO3 activates the Akt, Erk and β -Catenin cascade in neuronal cells and murine neurons. Significantly, Erk inhibitors reversed RSPO3-induced neuroprotection against OGD/R. Endothelial knockdown of RSPO3 inhibited Erk activation in the ischemic penumbra brain tissues, while endothelial RSPO3 overexpression enhanced it. These results support that RSPO3 activates Erk signaling to protect neuronal cells from ischemia/reperfusion injuries.

Our group has established the essential roles of Gai1/3 proteins in transducing the signaling of multiple receptors. Gai1/3 associated with epidermal growth factor (EGF)-activated EGFR is required for downstream Akt-mTOR activation [62]. Following brain-derived neurotrophic factor (BDNF) stimulation, Gai1/3 associates with TrkB to mediate downstream Akt-mTOR cascade activation [34]. Interestingly, Gai1/3, by forming a complex with CD14 and Gab1, is indispensable for mediating lipopolysaccharide (LPS)-induced signaling [70]. With interleukin 4 (IL-4) stimulation Gai1/3 associated with the intracellular domain of IL-4R α , promoting IL-4R α traffic and downstream Akt activation in macrophages [36]. A very recent study from our group found that Gai1/3 are also important for RSPO3-induced Akt-mTOR cascade activation, thereby promoting angiogenesis [31]. Gai1/3 associated with RSPO3-stimulated LGR4 and Gab1 to transduce downstream Akt-mTOR activation [31].

Recent studies have proposed a pivotal role of Gai1/3 in mediating Erk cascade activation. Li et al. have shown that in MEFs and endothelial cells, Netrin-1 treatment induced Gai1/3 association with its receptor CD146, leading to CD146 internalization, Gab1 recruitment and downstream Erk activation [32]. Shan et al. discovered that Gai1/3 can associate with SCF (stem cell factor)-stimulated receptor c-Kit in endothelial cells, causing c-Kit endocytosis and recruitment of adaptor proteins, thereby promoting downstream Erk activation [42]. Sun et al. reported that Gai1/3 was in the VEGFR2 (the VEGF receptor) endocytosis complex, required for VEGF-induced VEGFR2 endocytosis and downstream Erk activation [33]. Gai1/3 silencing, KO or DN mutation suppressed VEGF-induced Erk activation [33]. Wang et al. found that neuroligin-3 (NLGN3)-induced Erk activation also required Gai1 and Gai3 in glioma cells [35].

Here we further show that Gai1/3 proteins are vital for Erk activation. Importantly, RSPO3-induced Erk activation in neuronal cells was suppressed by Gai1/3 silencing, but augmented following ectopic Gai1/3 overexpression. RSPO3 induced LGR4-Gab1-Gai1/3 association was required for downstream Erk activation in neuronal cells. LGR4-Gab1 depletion largely inhibited RSPO3-induced Erk activation. An early study from our group discovered that knockdown of Gai1 and Gai3 decreased the number of dendrites and dendritic spines in hippocampal neurons [34]. Here, Gai1/3 silencing reversed RSPO3-induced neuroprotection against OGD/R. Together, these results demonstrate that RSPO3 activates LGR4-Gai1/3-Gab1-Erk signaling cascade, offering significant neuroprotection against cerebral ischemic injury (Fig. 10).

Interestingly, despite the high sequence homology, Gai1 and Gai3, but not Gai2, are key signaling proteins for RSPO3-induced Erk activation and neuronal protection. RSPO3 induces LGR4-Gab1-Gai1/3 association in neuronal cells, whereas Gai2 was not in the signaling complex. Xu et al. showed that Gai2 depletion




Fig. 10 The proposed signaling cascade of the present study.

failed to affect RSPO3-induced Akt-mTOR activation in endothelial cells [31]. Early studies have also demonstrated that Gai2 was not required for transducing signaling for RTKs and several non-RTK receptors [32–34, 42, 62, 70].

CONCLUSION

RSPO3 activates Gai1/3-Erk signaling to protect neuronal cells from ischemia/reperfusion injury. RSPO3 is a secretory protein. Our in vitro studies show that pretreatment with RSPO3 ameliorated OGD/R-induced oxidative injury and cell death in primary murine cortical neurons. In vivo, endothelial RSPO3 overexpression ameliorated MCAO-induced cerebral ischemic injury in mice. Therefore, targeting RSPO3 signaling pathway may have important therapeutic value for the treatment of ischemic stroke and other neuronal ischemia-reperfusion disorders.

DATA AVAILABILITY

The data are included in the article.

REFERENCES

- Campbell BCV, Khatri P. Stroke. *Lancet*. 2020;396:129–42.
- Pandian JD, Gall SL, Kate MP, Silva GS, Akinyemi RO, Ovbiagele BI, et al. Prevention of stroke: a global perspective. *Lancet*. 2018;392:1269–78.
- Shahjouei S, Sadighi A, Chaudhary D, Li J, Abedi V, Holland N, et al. A 5-Decade Analysis of Incidence Trends of Ischemic Stroke After Transient Ischemic Attack: A Systematic Review and Meta-analysis. *JAMA Neurol*. 2021;78:77–87.
- Mendelson SJ, Prabhakaran S. Diagnosis and Management of Transient Ischemic Attack and Acute Ischemic Stroke: A Review. *JAMA*. 2021;325:1088–98.
- Campbell BCV, De Silva DA, Macleod MR, Coutts SB, Schwamm LH, Davis SM, et al. Ischaemic stroke. *Nat Rev Dis Prim*. 2019;5:70.
- Verklan MT. The chilling details: hypoxic-ischemic encephalopathy. *J Perinat Neonatal Nurs*. 2009;23:59–68.
- Allen CL, Bayraktutan U. Oxidative stress and its role in the pathogenesis of ischaemic stroke. *Int J Stroke*. 2009;4:461–70.
- Xu S, Li Y, Chen JP, Li DZ, Jiang Q, Wu T, et al. Oxygen glucose deprivation/reoxygenation-induced neuronal cell death is associated with Lnc-D63785 m6A methylation and miR-422a accumulation. *Cell Death Dis*. 2020;11:816.

9. Zhao LP, Ji C, Lu PH, Li C, Xu B, Gao H. Oxygen glucose deprivation (OGD)/re-oxygenation-induced in vitro neuronal cell death involves mitochondrial cyclophilin-D/P53 signaling axis. *Neurochem Res.* 2013;38:705–13.
10. Gu DM, Lu PH, Zhang K, Wang X, Sun M, Chen GQ, et al. EGFR mediates astragaloside IV-induced Nrf2 activation to protect cortical neurons against in vitro ischemia/reperfusion damages. *Biochem Biophys Res Commun.* 2015;457:391–7.
11. Almeida A, Delgado-Esteban M, Bolanos JP, Medina JM. Oxygen and glucose deprivation induces mitochondrial dysfunction and oxidative stress in neurons but not in astrocytes in primary culture. *J Neurochem.* 2002;81:207–17.
12. Zhao H, Mitchell S, Ciechanowicz S, Savage S, Wang T, Ji X, et al. Argon protects against hypoxic-ischemic brain injury in neonatal rats through activation of nuclear factor (erythroid-derived 2)-like 2. *Oncotarget.* 2016;7:25640–51.
13. de Lau WB, Snel B, Clevers HC. The R-spondin protein family. *Genome Biol.* 2012;13:242.
14. Ter Steege EJ, Bakker ERM. The role of R-spondin proteins in cancer biology. *Oncogene.* 2021;40:6469–78.
15. Jin YR, Yoon JK. The R-spondin family of proteins: emerging regulators of WNT signaling. *Int J Biochem Cell Biol.* 2012;44:2278–87.
16. Zebisch M, Xu Y, Krastev C, MacDonald BT, Chen M, Gilbert RJ, et al. Structural and molecular basis of ZNRF3/RNF43 transmembrane ubiquitin ligase inhibition by the Wnt agonist R-spondin. *Nat Commun.* 2013;4:2787.
17. Chen PH, Chen X, Lin Z, Fang D, He X. The structural basis of R-spondin recognition by LGR5 and RNF43. *Genes Dev.* 2013;27:1345–50.
18. Xie Y, Zamponi R, Charlat O, Ramones M, Swalley S, Jiang X, et al. Interaction with both ZNRF3 and LGR4 is required for the signalling activity of R-spondin. *EMBO Rep.* 2013;14:1120–6.
19. Peng WC, de Lau W, Madoori PK, Forneris F, Granneman JC, Clevers H, et al. Structures of Wnt-antagonist ZNRF3 and its complex with R-spondin 1 and implications for signaling. *PLoS One.* 2013;8:e83110.
20. Wang D, Huang B, Zhang S, Yu X, Wu W, Wang X. Structural basis for R-spondin recognition by LGR4/5/6 receptors. *Genes Dev.* 2013;27:1339–44.
21. Xu K, Xu Y, Rajashankar KR, Robev D, Nikolov DB. Crystal structures of Lgr4 and its complex with R-spondin1. *Structure.* 2013;21:1683–9.
22. Lebensohn AM, Rohatgi R. R-spondins can potentiate WNT signaling without LGRs. *eLife.* 2018;7:e33126.
23. Ohkawara B, Glinka A, Niehrs C. Rspo3 binds syndecan 4 and induces Wnt/PCP signaling via clathrin-mediated endocytosis to promote morphogenesis. *Dev Cell.* 2011;20:303–14.
24. Scholz B, Korn C, Wojtarowicz J, Mogler C, Augustin I, Boutros M, et al. Endothelial RSP03 Controls Vascular Stability and Pruning through Non-canonical WNT/Ca(2+)/NFAT Signaling. *Dev Cell.* 2016;36:79–93.
25. Kazanskaya O, Ohkawara B, Heroult M, Wu W, Maltry N, Augustin HG, et al. The Wnt signaling regulator R-spondin 3 promotes angioblast and vascular development. *Development.* 2008;135:3655–64.
26. Cambier L, Plate M, Sucov HM, Pashmforoush M. Nkx2-5 regulates cardiac growth through modulation of Wnt signaling by R-spondin3. *Development.* 2014;141:2959–71.
27. Da Silva F, Rocha AS, Motamedi FJ, Massa F, Basboga C, Morrison H, et al. Coronary Artery Formation Is Driven by Localized Expression of R-spondin3. *Cell Rep.* 2017;20:1745–54.
28. Harnack C, Berger H, Antanaviciute A, Vidal R, Sauer S, Simmons A, et al. R-spondin 3 promotes stem cell recovery and epithelial regeneration in the colon. *Nat Commun.* 2019;10:4368.
29. Sigal M, Reines MDM, Mullerke S, Fischer C, Kapalczynska M, Berger H, et al. R-spondin-3 induces secretory, antimicrobial Lgr5(+) cells in the stomach. *Nat Cell Biol.* 2019;21:812–23.
30. Zhou B, Magana L, Hong Z, Huang LS, Chakraborty S, Tsukasaki Y, et al. The angiocrine R-spondin3 instructs interstitial macrophage transition via metabolic-epigenetic reprogramming and resolves inflammatory injury. *Nat Immunol.* 2020;21:1430–43.
31. Xu G, Qi LN, Zhang MQ, Li XY, Chai JL, Zhang ZQ, et al. Galphai1/3 mediation of Akt-mTOR activation is important for RSP03-induced angiogenesis. *Protein Cell.* 2023;14:217–22.
32. Li Y, Chai JL, Shi X, Feng Y, Li JJ, Zhou LN, et al. Galphai1/3 mediate Netrin-1-CD146-activated signaling and angiogenesis. *Theranostics.* 2023;13:2319–36.
33. Sun J, Huang W, Yang SF, Zhang XP, Yu Q, Zhang ZQ, et al. Galphai1 and Galphai3 mediate VEGF-induced VEGFR2 endocytosis, signaling and angiogenesis. *Theranostics.* 2018;8:4695–709.
34. Marshall J, Zhou XZ, Chen G, Yang SQ, Li Y, Wang Y, et al. Antidepressant action of BDNF requires and is mimicked by Galphai1/3 expression in the hippocampus. *Proc Natl Acad Sci USA.* 2018;115:E3549–58.
35. Wang Y, Liu YY, Chen MB, Cheng KW, Qi LN, Zhang ZQ, et al. Neuronal-driven glioma growth requires Galphai1 and Galphai3. *Theranostics.* 2021;11:8535–49.
36. Bai JY, Li Y, Xue GH, Li KR, Zheng YF, Zhang ZQ, et al. Requirement of Galphai1 and Galphai3 in interleukin-4-induced signaling, macrophage M2 polarization and allergic asthma response. *Theranostics.* 2021;11:4894–909.
37. Zhang YM, Zhang ZQ, Liu YY, Zhou X, Shi XH, Jiang Q, et al. Requirement of Galphai1/3-Gab1 signaling complex for keratinocyte growth factor-induced PI3K-AKT-mTORC1 activation. *J Invest Dermatol.* 2015;135:181–91.
38. Nicolicht-Amorim P, Delgado-Garcia LM, Nakamura TKE, Courbassier NR, Mosini AC, Porcionatto MA. Simple and efficient protocol to isolate and culture brain microvascular endothelial cells from newborn mice. *Front Cell Neurosci.* 2022;16:949412.
39. Liu H, Zhang Z, Xu M, Xu R, Wang Z, Di G. K6PC-5 Activates SphK1-Nrf2 Signaling to Protect Neuronal Cells from Oxygen Glucose Deprivation/Re-Oxygenation. *Cell Physiol Biochem: Int J Exp Cell Physiol, Biochem, Pharmacol.* 2018;51:1908–20.
40. Dordevic V, Stankovic Dordevic D, Kocic B, Dinic M, Sokolovic D, Pesic Stankovic J. The Impact of Hepatitis C Virus Genotypes on Oxidative Stress Markers and Catalase Activity. *Oxid Med Cell Longev.* 2021;2021:6676057.
41. Sahreen S, Khan MR, Khan RA. Hepatoprotective effects of methanol extract of *Carissa opaca* leaves on CCl4-induced damage in rat. *BMC Complement Altern Med.* 2011;11:48.
42. Shan HJ, Jiang K, Zhao MZ, Deng WJ, Cao WH, Li JJ, et al. SCF/c-Kit-activated signaling and angiogenesis require Galphai1 and Galphai3. *Int J Biol Sci.* 2023;19:1910–24.
43. Liu F, Chen G, Zhou LN, Wang Y, Zhang ZQ, Qin X, et al. YME1L overexpression exerts pro-tumorigenic activity in glioma by promoting Galphai1 expression and Akt activation. *Protein Cell.* 2023;14:223–9.
44. Guo YZ, Chen G, Huang M, Wang Y, Liu YY, Jiang Q, et al. TIMM44 is a potential therapeutic target of human glioma. *Theranostics.* 2022;12:7586–602.
45. Bian ZJ, Shan HJ, Zhu YR, Shi C, Chen MB, Huang YM, et al. Identification of Galphai3 as a promising target for osteosarcoma treatment. *Int J Biol Sci.* 2022;18:1508–20.
46. Shan HJ, Zhu LQ, Yao C, Zhang ZQ, Liu YY, Jiang Q, et al. MAFG-driven osteosarcoma cell progression is inhibited by a novel miRNA miR-4660. *Mol Ther Nucleic Acids.* 2021;24:385–402.
47. Lv Y, Wang Y, Song Y, Wang SS, Cheng KW, Zhang ZQ, et al. LncRNA PINK1-AS promotes G alpha i1-driven gastric cancer tumorigenesis by sponging microRNA-200a. *Oncogene.* 2021;40:3826–44.
48. Gao YY, Ling ZY, Zhu YR, Shi C, Wang Y, Zhang XY, et al. The histone acetyltransferase HBO1 functions as a novel oncogenic gene in osteosarcoma. *Theranostics.* 2021;11:4599–615.
49. Gong YQ, Huang W, Li KR, Liu YY, Cao GF, Cao C, et al. SC79 protects retinal pigment epithelium cells from UV radiation via activating Akt-Nrf2 signaling. *Oncotarget.* 2016;7:60123–32.
50. Jiang GL, Yang XL, Zhou HJ, Long J, Liu B, Zhang LM, et al. cGAS knockdown promotes microglial M2 polarization to alleviate neuroinflammation by inhibiting cGAS-STING signaling pathway in cerebral ischemic stroke. *Brain Res Bull.* 2021;171:183–95.
51. Zuo X, Lu J, Manaenko A, Qi X, Tang J, Mei Q, et al. MicroRNA-132 attenuates cerebral injury by protecting blood-brain-barrier in MCAO mice. *Exp Neurol.* 2019;316:12–9.
52. Yao J, Wu XY, Yu Q, Yang SF, Yuan J, Zhang ZQ, et al. The requirement of phosphoenolpyruvate carboxykinase 1 for angiogenesis in vitro and in vivo. *Sci Adv.* 2022;8:eabn6928.
53. Dijkhuis AJ, Klappe K, Jacobs S, Kroesen BJ, Kamps W, Sietsma H, et al. PDMP sensitizes neuroblastoma to paclitaxel by inducing aberrant cell cycle progression leading to hyperploidy. *Mol cancer Ther.* 2006;5:593–601.
54. Chaki S, Inagami T. Identification and characterization of a new binding site for angiotensin II in mouse neuroblastoma neuro-2A cells. *Biochem Biophys Res Commun.* 1992;182:388–94.
55. Wang P, Cui Y, Liu Y, Li Z, Bai H, Zhao Y, et al. Mitochondrial ferritin alleviates apoptosis by enhancing mitochondrial bioenergetics and stimulating glucose metabolism in cerebral ischemia reperfusion. *Redox Biol.* 2022;57:102475.
56. Yu L, Liu S, Zhou R, Sun H, Su X, Liu Q, et al. Atorvastatin inhibits neuronal apoptosis via activating cAMP/PKA/p-CREB/BDNF pathway in hypoxic-ischemic neonatal rats. *FASEB J: Off Publ Federation Am Societies Exp Biol.* 2022;36:e22263.
57. Chai WN, Wu YF, Wu ZM, Xie YF, Shi QH, Dan W, et al. Neat1 decreases neuronal apoptosis after oxygen and glucose deprivation. *Neural Regen Res.* 2022;17:163–9.
58. Zheng J, Qi J, Zou Q, Zhang Z. Construction of PLGA/JNK3-shRNA nanoparticles and their protective role in hippocampal neuron apoptosis induced by oxygen and glucose deprivation. *RSC Adv.* 2018;8:20108–16.
59. Zhang Q, Zhao S, Zheng W, Fu H, Wu T, Hu F. Plumbagin attenuated oxygen-glucose deprivation/reoxygenation-induced injury in human SH-SY5Y cells by inhibiting NOX4-derived ROS-activated NLRP3 inflammasome. *Biosci, Biotechnol, Biochem.* 2020;84:134–42.

60. Xin L, Junhua W, Long L, Jun Y, Yang X. Exogenous Hydrogen Sulfide Protects SH-SY5Y Cells from OGD/R-Induced Injury. *Curr Mol Med.* 2017;17:563–7.
61. Wu J, Li Q, Wang X, Yu S, Li L, Wu X, et al. Neuroprotection by curcumin in ischemic brain injury involves the Akt/Nrf2 pathway. *PLoS one.* 2013;8:e59843.
62. Cao C, Huang X, Han Y, Wan Y, Birnbaumer L, Feng GS, et al. Galpha(i1) and Galpha(i3) are required for epidermal growth factor-mediated activation of the Akt-mTORC1 pathway. *Sci Signal.* 2009;2:ra17.
63. Liu W, Ye Q, Xi W, Li Y, Zhou X, Wang Y, et al. The ERK/CREB/PTN/syndecan-3 pathway involves in heparin-mediated neuro-protection and neuro-regeneration against cerebral ischemia-reperfusion injury following cardiac arrest. *Int Immunopharmacol.* 2021;98:107689.
64. Zhao P, Yang JM, Wang YS, Hao YJ, Li YX, Li N, et al. Neuroprotection of Cytisine Against Cerebral Ischemia-Reperfusion Injury in Mice by Regulating NR2B-ERK/CREB Signal Pathway. *Neurochem Res.* 2018;43:1575–86.
65. Wang YY, Chang CY, Lin SY, Wang JD, Wu CC, Chen WY, et al. Quercetin protects against cerebral ischemia/reperfusion and oxygen glucose deprivation/reoxygenation neurotoxicity. *J Nutr Biochem.* 2020;83:108436.
66. Feng HX, Li CP, Shu SJ, Liu H, Zhang HY. A11, a novel diaryl acylhydrazone derivative, exerts neuroprotection against ischemic injury in vitro and in vivo. *Acta Pharmacol Sin.* 2019;40:160–9.
67. Chen Z, Zhang J, Yuan A, Han J, Tan L, Zhou Z, et al. R-spondin3 promotes the tumor growth of choriocarcinoma JEG-3 cells. *Am J Physiol Cell Physiol.* 2020;318:C664–74.
68. Gu H, Tu H, Liu L, Liu T, Liu Z, Zhang W, et al. RSPO3 is a marker candidate for predicting tumor aggressiveness in ovarian cancer. *Ann Transl Med.* 2020;8:1351.
69. Zhang M, Zhang P, Liu Y, Lv L, Zhang X, Liu H, et al. RSPO3-LGR4 Regulates Osteogenic Differentiation Of Human Adipose-Derived Stem Cells Via ERK/FGF Signalling. *Sci Rep.* 2017;7:42841.
70. Li X, Wang D, Chen Z, Lu E, Wang Z, Duan J, et al. Galpha1 and Galpha3 regulate macrophage polarization by forming a complex containing CD14 and Gab1. *Proc Natl Acad Sci USA.* 2015;112:4731–6.

ACKNOWLEDGEMENTS

We thank Dr. Chen at Jiangsu University for manuscript proofreading.

AUTHOR CONTRIBUTIONS

QJ, YZ, CC, XL, and JL conceived, designed, and supervised the study. TL, XS, HH, JC, QJ, YZ, CC, and XL collected and analyzed all in vitro and in vivo animal studies and analyzed the data. All authors drafted the article and revised it critically for important intellectual content, and with final approval of the version submitted to the journal.

FUNDING

This work was generously supported by grants from the National Natural Science Foundation of China (82371473, 81571282, 82172520, 82273055, 81771457, 81922025, 81773192, 81472786, 81802511, 81974388 and 81700859); Jiangsu

Province Social Development Project. A Project Funded by the Priority Academic Program Development of Jiangsu Higher Education Institutions; Suzhou Science and Technology Project (SYS2019044 and SKJY2021004) and National Key R&D Program of China (2017YFE0103700). Scientific Research Project of Jiangsu Provincial Health Commission (Z2022044 and M2022050). Gusu Health Talent Project of Suzhou City (GSWS2020040 and GSWS2019016). The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.

COMPETING INTERESTS

The authors declare no competing interests.

ETHICAL APPROVAL

This study was approved by the Ethics Committee of Soochow University.

ADDITIONAL INFORMATION

Supplementary information The online version contains supplementary material available at <https://doi.org/10.1038/s41419-023-06176-2>.

Correspondence and requests for materials should be addressed to Yun-Fang Zhen, Cong Cao, Xue-wu Liu or Jian-gang Liu.

Reprints and permission information is available at <http://www.nature.com/reprints>

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2023